Navigation Links
Prostate cancer drug reduces testosterone levels in as little as 3 days
Date:12/3/2008

actions, in contrast to other reported trials of other GnRH antagonists" points out Dr Klotz.

"The aim of the study was to show that degarelix was not inferior to leuprolide when it came to maintaining low testosterone levels over a one-year treatment period. We have conclusively shown that this is the case.

"However, we have also demonstrated that degarelix - which is an antagonist - offers an advantage, in that it reduces testosterone and PSA levels very quickly. It doesn't cause the initial surge of testosterone seen with agonist drugs like leuprolide - the other drug featured in this study.

"This is relevant as biochemical surges in testosterone can stimulate the prostate cancer cells and cause unpleasant side effects for patients. They may also require further drug therapy to counteract the effects of agonist drugs like leuprolide."


'/>"/>

Contact: Annette Whibley
wizard.media@virgin.net
Wiley-Blackwell
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. First biomarker discovered that predicts prostate cancer outcome
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Red wine compound shown to prevent prostate cancer
7. Barbershop Talks Cut Black Mens Prostate Cancer Risk
8. Generic prostate drug helps find high-risk cancers early
9. Finasteride unlikely to induce high grade prostate cancers
10. Shrinkage of prostate led to overestimation of cancer risk in trial
11. Prostate Cancer Awareness Week to Screen Thousands
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Cambridge Scientists Archive 500,000th Crystal Structure 2Gentiva Reports Second Quarter 2009 Results 53196 1Gentiva Reports Second Quarter 2009 Results 53196 2Gentiva Reports Second Quarter 2009 Results 53196 3Gentiva Reports Second Quarter 2009 Results 53196 4Gentiva Reports Second Quarter 2009 Results 53196 5Gentiva Reports Second Quarter 2009 Results 53196 6Gentiva Reports Second Quarter 2009 Results 53196 7Gentiva Reports Second Quarter 2009 Results 53196 8Gentiva Reports Second Quarter 2009 Results 53196 9Gentiva Reports Second Quarter 2009 Results 53196 10Gentiva Reports Second Quarter 2009 Results 53196 11Gentiva Reports Second Quarter 2009 Results 53196 12Gentiva Reports Second Quarter 2009 Results 53196 13Gentiva Reports Second Quarter 2009 Results 53196 14Gentiva Reports Second Quarter 2009 Results 53196 15Gentiva Reports Second Quarter 2009 Results 53196 16BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update 53194 1BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update 53194 2BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update 53194 3BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update 53194 4BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update 53194 5BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update 53194 6BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update 53194 7BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update 53194 8BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update 53194 9Caliper Life Sciences Reports Second Quarter 2009 Results 13273 1Caliper Life Sciences Reports Second Quarter 2009 Results 13273 2Caliper Life Sciences Reports Second Quarter 2009 Results 13273 3Caliper Life Sciences Reports Second Quarter 2009 Results 13273 4Caliper Life Sciences Reports Second Quarter 2009 Results 13273 5Caliper Life Sciences Reports Second Quarter 2009 Results 13273 6Caliper Life Sciences Reports Second Quarter 2009 Results 13273 7Caliper Life Sciences Reports Second Quarter 2009 Results 13273 8Caliper Life Sciences Reports Second Quarter 2009 Results 13273 9Caliper Life Sciences Reports Second Quarter 2009 Results 13273 10